Abstract
Recent progress in antihypertensive therapy has widened the selection of drugs, and large clinical trials have attracted attention to newer classes of antihypertensives. Consequently, the use of diuretics as antihypertensive agents has been relatively reduced, particularly since the newer drugs are associated with fewer adverse metabolic reactions. However, diuretics have a specific activity of removing sodium from the body fluid, thereby rendering the blood pressure insensitive to sodium intake, relieving the overload to systemic circulation, and normalizing the circadian rhythm of blood pressure from a non-dipper to a dipper pattern. At low doses, diuretics are known to be as effective as all other antihypertensive agents for reducing nearly all types of cardiovascular events. In this brief review, the indication for thiazide diuretics will be discussed based on the pathophysiology of hypertension and antihypertensive therapy with diuretics mainly from the point of view of sodium metabolism. Low-dose diuretics will continue to be an important agent in the treatment of hypertension, mostly in combination with vasodilators such as modulators of the renin-angiotensin system and calcium channel blockers.
Similar content being viewed by others
Article PDF
References
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007.
Psaty BM, Lumley T, Furberg CD, et al: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–2544.
Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
Kimura G, Brenner BM : The renal basis for salt sensitivity in hypertension, in Laragh JH, Brenner BM ( eds): Hypertension: Pathophysiology, Diagnosis and Management. New York, Raven Press, 1995, pp 1569–1588.
Saito F, Kimura G : Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship. Hypertension 1996; 27: 914–918.
Kimura G, Uzu T, Nakamura S, Inenaga T, Fujii T : High sodium sensitivity and glomerular hypertension/hyperfiltration in primary aldosteronism. J Hypertens 1996; 14: 1463–1468.
Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G : Effects of the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-natriuresis relationship. Hypertension 2003; 42: 8–13.
Zhou X, Matavelli LC, Ono H, Frohlich ED : Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. Am J Physiol Renal Physiol 2005; 289: F871–F879.
Brown MJ, Palmer CR, Castaigne A, et al: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–372.
de Leeuw PW, Ruilope LM, Palmer CR, et al: Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459–2464.
Fukuda M, Kimura G : Can calcium channel blockers preserve renal function better than diuretics during antihypertensive treatment? Arch Intern Med 2005; 165: 1312.
Marre M, Puig JG, Kokot F, et al: Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613–1622.
Uzu T, Harada T, Namba T, et al: Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. J Hypertens 2005; 23: 861–865.
Guyton AC : Arterial Pressure and Hypertension, Circulatory Physiology III. Philadelphia, WB Saunders, 1980.
Guyton AC : Renal function curve—a key to understanding the pathogenesis of hypertension. Hypertension 1987; 10: 1–6.
Guyton AC : Dominant role of the kidneys and accessory role of whole-body autoregulation in the pathogenesis of hypertension. Am J Hypertens 1989; 2: 575–585.
Appel LJ, Moore TJ, Obarzanek E, et al, DASH Collaborative Research Group: A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336: 1117–1124.
Sacks FM, Svetkey LP, Vollmer WM, et al: Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001; 344: 3–10.
Vollmer WM, Sacks FM, Ard J, et al: Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 2001; 135: 1019–1028.
Kimura G, Brenner BM : Implications of linear pressure-natriuresis relationship and importance of sodium sensitivity in hypertension. J Hypertens 1997; 15: 1055–1061.
Kimura G, Saito F, Kojima S, et al: Renal function curve in patients with secondary forms of hypertension. Hypertension 1987; 10: 11–15.
Parfrey PS : Salt in essential hypertension, in Sleight P, Freis ED ( eds): Hypertension. Butterworth's International Medical Reviews, Cardiology 1. London, Butterworth, 1982, pp 322–339.
Parfrey PS, Markandu ND, Roulstone JE, Jones BE, Johnes JC, MacGregor GA : Relation between arterial pressure, dietary sodium intake and renin system in essential hypertension. Br Med J 1981; 283: 94–97.
Kimura G, Deguchi F, Kojima S, et al: Antihypertensive drugs and sodium restriction. Analysis of their interaction based on pressure-natriuresis relationship. Am J Hypertens 1988; 1: 372–379.
Kimura G, Abe H, Ashida T, et al: Hypotensive mechanisms of antihypertensives based on the water tank model. Am J Hypertens 1989; 2: 532–536.
Materson BJ, Reda DJ, Cushman WC, et al, The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914–921.
Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ : Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002; 20: 771–777.
Morgan T, Lauri J, Bertram D, Anderson A : Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118–123.
SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.
MacMahon S, Rodgers A : The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967–978.
Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH : Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153: 578–581.
2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Williams B, Poulter NR, Brown MJ, et al: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV. J Hum Hypertens 2004; 18: 139–185.
Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension : Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613–634.
Uzu T, Kimura G : Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999; 100: 1635–1638.
Uzu T, Kazembe FS, Ishikawa K, Nakamura S, Inenaga T, Kimura G : High sodium sensitivity implicates nocturnal hypertension in essential hypertension. Hypertension 1996; 28: 139–142.
Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G : Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1997; 96: 1859–1862.
Fujii T, Uzu T, Nishimura M, et al: Circadian rhythm of natriuresis is disturbed in non-dipper type of essential hypertension. Am J Kidney Dis 1999; 33: 29–35.
Uzu T, Nishimura M, Fujii T, et al: Changes in the circadian rhythm of blood pressure in primary aldosteronism in response to dietary sodium restriction and adrenalectomy. J Hypertens 1998; 16: 1745–1748.
Harshfield GA, Alpert BS, Willey ES, Somes GW, Murphy JK, Dupaul LM : Race and gender influence ambulatory blood pressure patterns of adolescents. Hypertension 1989; 14: 598–603.
Agyemang C, Bhopal R, Bruijnzeels M, Redekop WK : Does nocturnal blood pressure fall in people of African and South Asian descent differ from that in European white populations? A systematic review and meta-analysis. J Hypertens 200; 23: 913–920.
Fukuda M, Munemura M, Usami T, et al: Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 2004; 65: 621–625.
Kimura G : Sodium, kidney, and circadian rhythm of blood pressure. Clin Exp Nephrol 2001; 5: 13–18.
O'Brien E, Sheridan J, O'Malley K : Dippers and non-dippers. Lancet 1988; 2: 397.
Verdecchia P, Schillaci G, Guerrieri M, et al: Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528–536.
Shimada K, Kawamoto A, Matsubayashi K, Ozawa T : Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension 1990; 16: 692–699.
Verdecchia P, Porcellati C, Schillaci G, et al: Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793–801.
Pickering TG : The clinical significance of diurnal blood pressure variations. Dippers and nondippers. Circulation 1990; 81: 700–702.
Staessen JA, Thijs L, Fagard R, et al, Systolic Hypertension in Europe Trial Investigators : Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282: 539–546.
Mancia G, Facchetti R, Bombelli M, et al: Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45: 1072–1077.
Dolan E, Stanton A, Thijs L, et al: Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46: 156–161.
Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S : Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–636.
K/DOQI clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 ( 2 Suppl 1): S1–S266.
Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–2169.
Ritz E, McClellan WM : Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol 2004; 15: 513–516.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305.
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR : Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225–232.
Goto N, Uchida K, Morozumi K, et al: Circadian blood pressure rhythm is disturbed by nephrectomy. Hypertens Res 2005; 28: 301–306.
Kimura G : Glomerular function reserve and sodium sensitivity. Clin Exp Nephrol 2005; 9: 102–113.
Morimoto A, Uzu T, Fujii T, et al: Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1997; 350: 1734–1737.
Kimura G : Sodium sensitivity of blood pressure: a new prognostic factor in hypertension. Nephron 1999; 83: 97–105.
Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M : Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 2001; 37 ( 2 Part 2): 429–432.
Law MR, Wald NJ, Morris JK, Jordan RE : Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
Siscovick DS, Raghunathan TE, Psaty BM, et al: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852–1857.
Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB : Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025–1030.
Verdecchia P, Reboldi G, Angeli F, et al: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963–969.
Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR : Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29–35.
Inaba M, Noguchi Y, Yamamoto T, et al: Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters. Hypertens Res 2004; 27: 141–145.
Doulton TW, He FJ, MacGregor GA : Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880–886.
Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Lindholm LH, Ibsen H, Dahlof B, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–1010.
Dahlof B, Devereux RB, Kjeldsen SE : Diuretics in the LIFE study. Lancet 2004; 364: 413–414.
Dahlof B, Sever PS, Poulter NR, et al: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
Poulter NR, Wedel H, Dahlof B, et al: Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907–913.
Epstein M, Messerli FM : Combination therapy in the management of hypertension, in Messerli FM ( ed): The ABCs of Antihypertensive Therapy. New York, Authors' Publishing House, 2000; pp 204–221.
Kaplan NM : Clinical Hypertension. Philadelphia, Lippincott, 2002.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fukuda, M., Kimura, G. Pathophysiology of Antihypertensive Therapy with Diuretics. Hypertens Res 29, 645–653 (2006). https://doi.org/10.1291/hypres.29.645
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.29.645
Keywords
This article is cited by
-
Urinary Albumin Excretion During Angiotensin II Receptor Blockade: Comparison of Combination Treatment With a Diuretic or a Calcium-Channel Blocker
American Journal of Hypertension (2011)
-
Augmented antihypertensive effect of a fixed combination formula of candesartan and hydrochlorothiazide combined with furosemide in a patient on peritoneal dialysis
Clinical and Experimental Nephrology (2011)
-
Effectiveness of open-label losartan/hydrochlorothiazide combination therapy in Asian patients with hypertension not controlled with ACE inhibitor or ARB monotherapy
Hypertension Research (2009)